相关实验视频

Updated: Jul 10, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

在胰腺癌中,MUC1对化疗的耐药性的进展

Youhao Yao^1,2, Daguang Fan²

¹The Fifth Clinical Medical College of Shanxi Medical University, Shanxi, PR China.

Journal of chemotherapy (Florence, Italy)

|November 25, 2023

概括

胰腺癌 (PC) 化学抵抗性正在增加. 异常糖化MUC1蛋白驱动这种耐药性,这表明针对MUC1的疗法可以改善胰腺癌患者的治疗结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生物化学

背景情况:

全球胰腺癌发病率和死亡率正在上升.
化疗耐药性显著限制了PC的治疗疗效.
甲1 (MUC1) 是一种跨膜蛋白,与癌症的进展和化学抵抗有关.

研究的目的:

阐明MUC1有助于胰腺癌化学抵抗的机制.
审查PC目前和新兴的MUC1向治疗策略.

主要方法:

对研究MUC1在癌症生物学中的作用的文献综述.
对MUC1糖基化模式和化学抵抗研究的分析.
在临床前和临床环境中,综合了基于MUC1的向疗法数据.

主要成果:

异常甘油化MUC1的过度表达是胰腺癌细胞发展化疗抵抗的关键因素.
MUC1影响多种信号通路,促进化学疗法下癌细胞的存活.
一些针对MUC1的方法,包括抗体和抑制剂,显示出有前途.

结论:

MUC1在胰腺癌中介化疗抵抗方面发挥着至关重要的作用.
向MUC1提供了一种潜在的策略,以克服治疗耐药性并改善PC患者的治疗结果.
进一步开发基于MUC1的疗法对于胰腺癌治疗是有必要的.

关键词:

在MUC1中,MUC1是MUC1.在MUC1的抗体.这是一种MUC1抑制剂.在MUC1疫苗疫苗中.化学电阻是一种化学电阻.胰腺癌是一种癌症.

更多相关视频

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...